Description: Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Home Page: www.lexeotx.com
345 Park Avenue South
New York,
NY
10010
United States
Phone:
212-547-9879
Officers
| Name | Title |
|---|---|
| Mr. R. Nolan Townsend | CEO & Director |
| Dr. Eric Adler M.D. | Chief Medical Officer & Head of Research |
| Ms. Jenny R. Robertson J.D. | Chief Business & Legal Officer |
| Dr. Ronald G. Crystal M.D. | Co-Founder, Chief Scientific Advisor & Member of Scientific Advisory Board |
| Mr. Rand Monaghan | Vice President of Finance |
| Dr. Jose Manuel Otero Ph.D. | Chief Technical Officer |
| Dr. Sandi See Tai M.D. | Chief Development Officer |
| Mr. Ryan McHenry | VP & Corporate Controller |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.6927 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-11-03 |
| Fiscal Year End: | December |
| Full Time Employees: | 69 |